US OptionsDetailed Quotes
WVE241018P7500
- 0.30
- +0.04+15.38%
15min DelayClose Oct 4 16:00 ET
0.30High0.25Low
0.25Open0.26Pre Close56 Volume1.21K Open Interest7.50Strike Price1.46KTurnover137.26%IV14.39%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier11DDays to Expiry0.30Extrinsic Value100Contract SizeAmericanOptions Type-0.2758Delta0.1620Gamma21.03Leverage Ratio-0.0298Theta-0.0008Rho-5.80Eff Leverage0.0050Vega
Wave Life Sciences Stock Discussion
In a notable transaction, GSK (LON:GSK) plc, a major player in the pharmaceutical industry, has recently increased its stake in Wave Life Sciences Ltd . (NASDAQ:WVE). The acquisition involved the purchase of 2,791,930 ordinary shares at a price of $8.00 per share, amounting to a total investment of $22.3 million.
This strategic move by GSK plc, which is known for its diverse portfolio of healthca...
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
Wave Life Sciences announced positive interim data from the FORWARD-53 clinical trial evaluating WVE-N531 in boys with Duchenne Muscular Dystrophy (DMD) amenable to exon 53 skipping. Key findings include:
- Mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of ...
Wave Life Sciences Announces FDA Has Granted Rare Pediatric Disease Designation To WVE-N531 For Treatment Of Duchenne Muscular Dystrophy
No comment yet